Press Releases Press Releases Keyword Search Year None202120202019201820172016201520142013 08 Sep '2021 Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech’s Natrunix™ Anti-Cancer Therapy in Pancreatic Cancer 30 Aug '2021 XBiotech Announces Addition of Dr. Mark Ziats, M.D. Ph.D. as Medical Director 30 Jul '2021 XBiotech Announces Payment of Dividend to Holders of Common Stock 06 Jul '2021 XBiotech Announces Dividend to Holders of Common Stock 30 Jun '2021 XBiotech Announces Receipt of $75 Million from Sale of Antibody 23 Jun '2021 XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer 03 May '2021 French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotech’s New Cancer Drug for Colorectal Cancer 19 Apr '2021 FDA Gives Go-Ahead for XBiotech’s Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer 21 Jan '2021 XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain 19 Jan '2021 XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy
Press Releases Keyword Search Year None202120202019201820172016201520142013 08 Sep '2021 Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech’s Natrunix™ Anti-Cancer Therapy in Pancreatic Cancer 30 Aug '2021 XBiotech Announces Addition of Dr. Mark Ziats, M.D. Ph.D. as Medical Director 30 Jul '2021 XBiotech Announces Payment of Dividend to Holders of Common Stock 06 Jul '2021 XBiotech Announces Dividend to Holders of Common Stock 30 Jun '2021 XBiotech Announces Receipt of $75 Million from Sale of Antibody 23 Jun '2021 XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer 03 May '2021 French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotech’s New Cancer Drug for Colorectal Cancer 19 Apr '2021 FDA Gives Go-Ahead for XBiotech’s Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer 21 Jan '2021 XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain 19 Jan '2021 XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy
08 Sep '2021 Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech’s Natrunix™ Anti-Cancer Therapy in Pancreatic Cancer
23 Jun '2021 XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer
03 May '2021 French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotech’s New Cancer Drug for Colorectal Cancer
19 Apr '2021 FDA Gives Go-Ahead for XBiotech’s Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer
21 Jan '2021 XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain
19 Jan '2021 XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy
